Influence of Systemic Propranolol Treatment on the Physical Development of Paediatric Patients With Infantile Hemangiomas
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 128
- Primary Endpoint
- Change on the height of the patients
Study Overview
Brief Summary
This is retrospective study. The patients treated with oral propranolol at a dose of 2.0 mg/kg per day. Growth parameters (height and weight) were measured at the beginning, the end of treatment and 2 years after treatment. The weight-for-age Z-score (WAZ), height-for-age Z-score (HAZ) and weight-for-height Z-score (WHZ) calculated by the WHO Anthro software were used to assess physical development, and the WHO Child Growth Standards were used as the standards.
Study Design
- Study Type
- Observational
- Observational Model
- Case Crossover
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 2 Weeks to 54 Weeks (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •IHs diagnosed by medical history and physical examination
- •no previous treatment with other medications
Exclusion Criteria
- •a history or risk of asthma, reactive airway disease, impaired renal or liver function, heart defects or arrhythmia, hypotension and hypersensitivity to propranolol
- •Infants who did not adhere to the treatments or attend follow-up visits
- •Infants with other known risk factors for developmental delay or growth restriction, such as prematurity, small for gestational age, or other major congenital malformations, were also excluded
- •No other treatment was used during the oral propranolol course
Arms & Interventions
Propranolol treatment group
Intervention: propranolol (Drug)
Outcomes
Primary Outcomes
Change on the height of the patients
Time Frame: at the beginning of the treatment, at the end of treatment and 2 years after the treatment
we recorded the height of the patients in meters.
Change on the weight of the patients
Time Frame: at the beginning of the treatment, at the end of treatment and 2 years after the treatment
we recorded the weight of the patients in kilograms.
Secondary Outcomes
No secondary outcomes reported